Skip to main content
Celemics, Inc. logo

Celemics, Inc. — Investor Relations & Filings

Ticker · 331920 ISIN · KR7331920009 KO Manufacturing
Open in API
Filings indexed 179 across all filing types
Latest filing 2026-02-04 Capital/Financing Update
Country KR South Korea
Listing KO 331920

About Celemics, Inc.

https://www.celemics.com/

Celemics, Inc. is a biotechnology company that develops and provides Next-Generation Sequencing (NGS) solutions for research and clinical applications. The company specializes in hybridization-based target enrichment technology, offering a comprehensive portfolio of products and services. This includes ready-to-use and customized NGS panels, whole exome sequencing kits, library preparation kits, modular accessories, and bioinformatics analysis services. Celemics' solutions support a wide range of fields, including oncology (somatic cancer, liquid biopsy), inherited diseases, pathogen analysis, pharmacogenomics, and immune repertoire profiling. A key focus is the development of end-to-end customized target enrichment panels, providing support from assay design and optimization to complete bioinformatics analysis. The company's proprietary technologies in probe design and molecular barcoding enable efficient analysis of diverse and challenging sample types.

Recent filings

Filing Released Lang Actions
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding a 'Decision on Paid-in Capital Increase' (유상증자결정) filed with the Korea Exchange. It details the issuance of new shares, the purpose of the capital raise, the third-party allocation details, and the pricing methodology. This falls under the category of capital structure changes and financing activities.
2026-02-04 Korean
최대주주변경을수반하는주식양수도계약체결
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from a Korean company (Celemix) announcing a 'Change in Largest Shareholder' due to a stock purchase agreement. This type of disclosure is a standard regulatory requirement for public companies to inform the market about changes in control and major shareholding structures. It does not fit into specific categories like 'Director's Dealing' (which is for individual insider trades) or 'Major Shareholding Notification' (which is usually filed by the shareholder). Given the nature of the announcement regarding corporate control and ownership structure, it falls under the 'Regulatory Filings' (RNS) category as a general corporate disclosure.
2026-02-03 Korean
주주총회소집결의 (임시주주총회)
AGM Information Classification · 1% confidence The document is a formal notice of an Extraordinary General Meeting (임시주주총회) for the company Celemix. It details the date, location, and agenda items (election of directors and auditors) for the upcoming meeting. This type of document is a standard proxy solicitation or notice of meeting, which falls under the Proxy Solicitation & Information Statement category.
2026-02-03 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (임시주주총회). It does not contain the full proxy materials or the meeting results, but rather serves as a formal notice of the record date for shareholder rights. Given it is a standard regulatory notification regarding corporate governance and shareholder meetings that does not fit into specific categories like DVA or PSI, it is classified as a general regulatory filing.
2026-02-03 Korean
단일판매ㆍ공급계약체결(자율공시)
Regulatory Filings Classification · 1% confidence The document is a formal disclosure of a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) by the company Celemix. It details the contract value, the counterparty (Korea Disease Control and Prevention Agency), and the contract duration. Since this is a specific corporate announcement regarding a business contract that does not fit into the other specialized categories like M&A or financial reports, it falls under the general regulatory filing category.
2025-12-24 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Celemics, Inc.' covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business operations, management discussions, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2025
2025-08-13 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.